Telix completes patient enrollment in Phase 3 BiPASS study
Telix Pharmaceuticals Limited announced completion of patient enrollment in its Phase 3 BiPASS study for commercial PSMA-PET1 imaging agents, Illuccix.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
TLX completes enrollment in Phase 3 BiPASS study
TLX says it has completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on the NDA pathway.